Pharmaceuticals

VELETRI Market 2026–2030 evolving with increasing therapeutic applications

March 25, 2026March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The VELETRI Market During 2026–2030?

The veletri market has experienced strong expansion in recent years. Its size is expected to increase from $1.45 billion in 2025 to $1.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This historic growth is due to several factors, including the clinical effectiveness of epoprostenol, a rise in the diagnosis of PAH, hospitals’ reliance on IV prostacyclins, the scarcity of oral treatment options, and improved survival rates for PAH patients.

The veletri market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $2.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast timeframe is attributable to factors such as a rise in pah prevalence, the expansion of specialized pah centers, a greater need for stable drug formulations, wider acceptance of infusion therapy, and enhanced awareness regarding pah. Key trends projected for this period involve the increasing uptake of non-refrigerated prostacyclin treatments, more frequent application of continuous infusion pah therapies, a surge in demand for sophisticated pah vasodilators, the broadening of hospital-centric pah management approaches, and a heightened emphasis on enhancing the mobility of pah patients.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21314&type=smp

Which Economic Or Industry Drivers Are Impacting The VELETRI Market?

The VELETRI market is projected to expand due to the rising occurrence of venous diseases, which are conditions involving diminished blood flow in veins, resulting in discomforts such as swelling and pain, and potentially leading to complications like varicose veins and deep vein thrombosis. The heightened incidence of venous diseases is influenced by factors including an aging global demographic, inactive routines, higher rates of obesity, and advancements in diagnostic methods. VELETRI provides benefits by enhancing exercise capacity and alleviating symptoms for individuals suffering from venous diseases that impact the pulmonary vasculature. For example, data from January 2025, released by the US-based government organization, the Centers for Disease Control and Prevention, indicates that each year up to 900,000 people in the United States are affected by venous thromboembolism (VTE), a blood clot condition, and an estimated 60,000 to 100,000 deaths annually are linked to VTE. Consequently, the growing prevalence of venous diseases is a key driver for the expansion of the VELETRI market.

How Are The Various Segments Of The VELETRI Market Categorized?

The veletri market covered in this report is segmented –

1) By Formulation Stability Type: Room-Temperature Stable Formulation, Refrigeration-Required Formulation

2) By Treatment Setting: Hospitals, Specialized Pulmonary Hypertension Centers

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Room-Temperature Stable Formulation: Ready-to-Use Formulation, Extended Stability Infusion Solution

2) By Refrigeration-Required Formulation: Reconstituted Cold-Chain Formulation, Limited-Stability Infusion Solution

What Trends Are Affecting The Expansion Of The VELETRI Market?

Companies operating significantly in the Veletri market are prioritizing expanded access through generic drug formulations, such as the FDA-approved epoprostenol sodium injection, to offer more economical treatment solutions for patients with pulmonary arterial hypertension. Generic Veletri refers to versions of the branded epoprostenol product that are therapeutically equivalent and meet FDA standards for quality, safety, and efficacy, providing the same clinical benefits at a reduced cost. For instance, in October 2025, Mylan Pharmaceuticals, a US-based pharmaceutical company, obtained FDA approval for its generic Veletri (epoprostenol sodium) injection. This product is supplied in multiple vial strengths, including 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and delivers the identical prostacyclin mimetic activity as the original version, aiding in the improvement of exercise tolerance and symptom management for PAH patients.

Which Major Firms Influence Developments In The VELETRI Market?

Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc

Read the full veletri market report here:

https://www.thebusinessresearchcompany.com/report/veletri-global-market-report

What Are The Top-Performing Regions Within The VELETRI Market?

North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored VELETRI Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21314&type=smp

Browse Through More Reports Similar to the Global VELETRI Market 2026, By The Business Research Company

Vermiculite Market Report 2026

https://www.thebusinessresearchcompany.com/report/vermiculite-global-market-report

Vanadium Market Report 2026

https://www.thebusinessresearchcompany.com/report/vanadium-global-market-report

Gelatin Market Report 2026

https://www.thebusinessresearchcompany.com/report/gelatin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795